Study to Evaluate Immunological Response to PD-1 Inhibition in Squamous Cell Carcinoma of the Head and Neck (SCCHN)
A Pilot Study to Evaluate Immunological Response to PD-1 Inhibition in Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Sponsor: CellSight Technologies, Inc.
A PHASE1 clinical study on Squamous Cell Carcinoma of the Head and Neck, this trial is completed. The trial is conducted by CellSight Technologies, Inc. and has accumulated 12 data snapshots since 2017. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
Apr 2022 — Jan 2023 [monthly]
Recruiting PHASE1
-
Feb 2021 — Apr 2022 [monthly]
Recruiting PHASE1
Status: Active Not Recruiting → Recruiting
▶ Show 7 earlier versions
-
Jan 2021 — Feb 2021 [monthly]
Active Not Recruiting PHASE1
-
Jun 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Aug 2019 — Jun 2020 [monthly]
Recruiting PHASE1
-
Feb 2019 — Aug 2019 [monthly]
Recruiting PHASE1
-
Jun 2018 — Feb 2019 [monthly]
Recruiting PHASE1
-
Dec 2017 — Jun 2018 [monthly]
Recruiting PHASE1
-
Jun 2017 — Dec 2017 [monthly]
Recruiting PHASE1
First recorded
May 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- CellSight Technologies, Inc.
- Stanford University
For direct contact, visit the study record on ClinicalTrials.gov .